Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807231 | 0.88 | CHRM3 (0.54) | CHRM3CHRM2OPRD1CHRM1OPRM1 | |
| SCHEMBL14507949 | 0.84 | CHRM3 (0.53) | CHRM3CHRM2OPRD1CHRM1OPRM1 | |
| SCHEMBL5164451 | 0.84 | OPRM1 (0.72) | CHRM3OPRD1CHRM1OPRM1OPRK1 | |
| SCHEMBL684578 | 0.83 | OPRM1 (0.77) | CHRM3OPRD1CHRM1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL23805142 | 0.83 | OPRD1 (0.61) | CHRM3CHRM2OPRD1CHRM1OPRM1 | |
| SCHEMBL6601536 | 0.83 | KDM4E (0.64) | CHRM3CHRM2OPRD1 | |
| SCHEMBL6045443 | 0.82 | CHRM2 (0.83) | CHRM3CHRM2OPRM1SIGMAR1DRD2 | |
| SCHEMBL2675253 | 0.82 | OPRM1 (0.55) | CHRM3CHRM2OPRD1CHRM1CHRM4 | |
| SCHEMBL13681469 | 0.81 | OPRD1 (0.49) | CHRM3CHRM2OPRD1CHRM1OPRM1 | |
| SCHEMBL9776407 | 0.81 | LMNA (0.51) | CHRM3CHRM2OPRD1CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-11091456-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| EP-3822262-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3331869-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20190270718-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10351545-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-10167272-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20180155315-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180155315-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091456-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885OPRD1 183/4885 |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | CHRM3 134/4885CHRM2 421/4885OPRD1 97/4885 |
| US-20180022726-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885OPRD1 183/4885 |
| US-20190270718-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885OPRD1 183/4885 |
| US-10351545-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885OPRD1 183/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | CHRM3 134/4885CHRM2 421/4885OPRD1 97/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885OPRD1 183/4885 |
| US-20180155315-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885OPRD1 183/4885 |
| US-10167272-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885OPRD1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.